We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Celiac Disease Blood Test to Eliminate Painful Biopsies

By LabMedica International staff writers
Posted on 21 Sep 2023
Print article
Image: Biopsy-free diagnosis of celiac disease in adults has shown promising results (Photo courtesy of Freepik)
Image: Biopsy-free diagnosis of celiac disease in adults has shown promising results (Photo courtesy of Freepik)

There is still a controversy over whether it is possible to diagnose celiac disease in adults using only serology. Now, a study has found that a simple test for measuring the levels of anti-tissue transglutaminase IgA (tTG-IgA) in the blood could be used as a diagnostic threshold in predicting duodenal villous atrophy, a key feature of celiac disease.

Researchers from the University of Salerno (Fisciano SA, Italy) conducted a study on a cohort of individuals suspected to have celiac disease. After certain exclusions, the final cohort included 436 individuals, comprising 296 women and 140 men, with an average age of 40. These participants hailed from various global regions, mostly Europe, followed by Asia, Oceania, and South America.

Based on their symptoms, the participants were divided into three categories: those showing classical symptoms like anemia, weight loss, or diarrhea; those with atypical symptoms; and those who were suspected to have celiac disease based on family history or other associated autoimmune conditions. Duodenal tissue samples were collected from the participants via endoscopy and were assessed by local pathologists at 14 different sites. Additionally, tTG-IgA levels were measured in both local and central labs. A result was considered positive if tTG-IgA levels exceeded one time the upper limit of normal (ULN).

Out of the cohort, 363 participants (or 83%) had tTG-IgA levels above the threshold, while 73 (or 17%) had levels below it. Among those with elevated tTG-IgA, 341 were confirmed to have celiac disease through histological review, whereas 22 did not have the disease. Of the participants with low tTG-IgA, seven were false negatives with positive histology, and 66 were true negatives. Importantly, the study found that tTG-IgA concentrations that were 5, 10, or 15 times higher than the ULN offered the most reliable diagnostic accuracy, suggesting that 10 times the ULN could be a useful diagnostic threshold. This study validates the use of a blood test for diagnosing celiac disease in adults, similar to the "no-biopsy" approach currently used in children. The detailed findings of the study were published in The Lancet Gastroenterology & Hepatology.

Related Links:
University of Salerno

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit
New
Silver Member
ACTH Assay
ACTH ELISA

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.